Aripiprazole (Abilify) + Ziprasidone Hydrochloride (Geodon)
FDA label text mentions this combination without strong caution language. It is still worth confirming with your prescriber or pharmacist.
Basis: Warnings section of the Ziprasidone Hydrochloride FDA label.
Ziprasidone hydrochloride is not approved for the treatment of patients with dementia-related psychosis. [see Boxed Warning , Warnings and Precautions (5.2)] . 5.2 Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients With Dementia-Related Psychosis In placebo-controlled trials in elderly subjects with dementia, patients randomized to risperidone, aripiprazole, and olanzapine had a higher incidence of stroke and transient ischemic attack, including fatal stroke.
Excerpt from the FDA prescribing label for Ziprasidone Hydrochloride (SPL set ID 0fcebd61-25b2-d287-e063-6394a90a7b9a).
About this interaction data. These interactions were identified by automatically scanning FDA prescribing-label text for medications in Bridgeway's library. This is not a complete list and is not a substitute for review by your prescriber or pharmacist, who use comprehensive clinical databases. Always share your full medication list with your care team. How we source this data →
Bridgeway's Utah prescribers coordinate medication management with therapy — so interactions like this one are reviewed by people who see your whole picture.
Request an Appointment Call (801) 255-5131Not medical advice. This page summarizes publicly available FDA drug labeling alongside general guidance from Bridgeway Integrated Healthcare Services. It is for educational purposes only and is not a substitute for advice from your prescriber or pharmacist. Never start, stop, or change a medication without talking to your healthcare provider. In an emergency, call 911.